Kindstar Globalgene Technology, Inc. provided unaudited consolidated earnings guidance for the six months ended June 30, 2022. For the period, the company expects the profit attributable to the Shareholders for first half of 2022 is expected to be within the range of RMB 60 million to RMB 68 million, representing a turnaround from loss to profit compared to the corresponding period in 2021. The expected turnaround from unaudited loss to profit attributable to the Shareholders was mainly due to the fact that: there was no substantial fair value loss on financial liabilities at fair value through profit or loss (FVTPL) comparing with the corresponding period of 2021; and the growth in revenue of testing services has driven an increase in profit.